Sunesis Pharmaceuticals Company Profile (NASDAQ:SNSS)

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals logoSunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company's other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: SNSS
  • CUSIP: 86732860
Key Metrics:
  • Previous Close: $4.30
  • 50 Day Moving Average: $4.06
  • 200 Day Moving Average: $4.14
  • 52-Week Range: $2.63 - $6.30
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.04
  • P/E Growth: -0.01
  • Market Cap: $89.78M
  • Outstanding Shares: 20,878,000
  • Beta: 1.88
Profitability:
  • Net Margins: -1,623.12%
  • Return on Equity: -806.43%
  • Return on Assets: -111.92%
Debt:
  • Current Ratio: 2.39%
  • Quick Ratio: 2.39%
Additional Links:
Companies Related to Sunesis Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Sunesis Pharmaceuticals (NASDAQ:SNSS) (?)
Ratings Breakdown: 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: N/A

Analysts' Ratings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Show:
DateFirmActionRatingPrice TargetDetails
12/28/2016Cantor FitzgeraldDowngradeBuy -> HoldView Rating Details
11/3/2016Cowen and CompanyReiterated RatingHoldView Rating Details
7/29/2016Wells Fargo & CoUpgradeMarket Perform -> OutperformView Rating Details
7/24/2015Roth CapitalDowngradeBuy -> Sell$5.50 -> $1.00View Rating Details
7/2/2015WedbushReiterated RatingHold$2.00View Rating Details
(Data available from 2/28/2015 forward)

Earnings

Earnings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
11/3/2016Q316($0.71)($0.62)$0.60 million$0.60 millionViewN/AView Earnings Details
7/29/2016Q216($0.10)($0.12)$0.70 million$0.60 millionViewListenView Earnings Details
5/5/2016Q116($0.12)($0.12)$0.77 million$0.64 millionViewListenView Earnings Details
3/10/2016Q415($0.14)($0.15)$0.84 million$0.67 millionViewListenView Earnings Details
11/5/2015Q315($0.12)($0.09)$1.09 million$0.68 millionViewListenView Earnings Details
7/30/2015Q215($0.13)($0.15)$1.21 million$0.85 millionViewN/AView Earnings Details
5/5/2015Q115($0.16)($0.13)$1.14 million$0.90 millionViewListenView Earnings Details
3/12/2015Q414($0.20)($0.02)$1.17 million$0.90 millionViewListenView Earnings Details
11/10/2014Q314($0.17)($0.25)$1.97 million$0.85 millionViewListenView Earnings Details
8/5/2014Q214($0.17)($0.20)$1.32 million$2.00 millionViewListenView Earnings Details
5/7/2014Q114($0.17)($0.26)$1.32 million$2.00 millionViewListenView Earnings Details
3/6/2014Q413($0.20)($0.15)$1.37 million$2.00 millionViewListenView Earnings Details
11/12/2013Q313($0.20)($0.16)$1.44 million$1.99 millionViewListenView Earnings Details
7/29/2013Q2 2013($0.21)$0.18$1.22 million$1.99 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.20)($0.23)$0.75 million$1.99 millionViewListenView Earnings Details
3/13/2013Q4 2012($0.19)($0.20)$0.32 million$1.99 millionViewListenView Earnings Details
11/8/2012Q312($0.11)($0.37)$4.17 million$0.26 millionViewN/AView Earnings Details
8/9/2012($0.20)($0.20)ViewN/AView Earnings Details
5/15/2012($0.18)($0.30)ViewN/AView Earnings Details
11/14/2011($0.18)($0.11)ViewN/AView Earnings Details
8/11/2011($0.15)($0.18)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Current Year EPS Consensus Estimate: $-2.44 EPS
Next Year EPS Consensus Estimate: $-2.11 EPS

Dividends

Dividend History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Insider Ownership Percentage: 14.05%
Institutional Ownership Percentage: 34.30%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/9/2016Geoffrey M ParkerDirectorBuy3,740$3.87$14,473.80View SEC Filing  
5/26/2016Geoffrey M ParkerDirectorBuy9,500$0.47$4,465.00View SEC Filing  
5/25/2016Geoffrey M ParkerDirectorBuy52,505$0.47$24,677.35View SEC Filing  
12/21/2015Dayton MisfeldtDirectorBuy1,750,000$0.84$1,470,000.00View SEC Filing  
8/25/2015Daniel N Swisher JrCEOBuy12,216$1.01$12,338.16View SEC Filing  
8/24/2015Daniel N Swisher JrCEOBuy12,784$1.01$12,911.84View SEC Filing  
8/29/2014Forest BaskettMajor ShareholderSell266,700$7.97$2,125,599.00View SEC Filing  
8/28/2014Bay City Capital LlcMajor ShareholderSell300,700$7.98$2,399,586.00View SEC Filing  
8/28/2014Dayton MisfeldtDirectorSell200,000$7.89$1,578,000.00View SEC Filing  
8/27/2014Adam R CraigCMOSell2,554$8.00$20,432.00View SEC Filing  
8/27/2014Daniel N Swisher JrCEOSell5,000$8.00$40,000.00View SEC Filing  
8/27/2014Dayton MisfeldtDirectorSell100,700$8.16$821,712.00View SEC Filing  
8/27/2014Eric BjerkholtCFOSell10,000$8.00$80,000.00View SEC Filing  
8/27/2014Krishna Kittu KolluriMajor ShareholderSell108,300$8.17$884,811.00View SEC Filing  
8/12/2014Dayton MisfeldtDirectorSell743,700$6.64$4,938,168.00View SEC Filing  
8/12/2014Equity Opportunities Fu GrowthMajor ShareholderSell710,540$6.63$4,710,880.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Sunesis Pharmaceuticals (NASDAQ:SNSS)
DateHeadline
finance.yahoo.com logoAchillion (ACHN) Reports Narrower-Than-Expected Q4 Loss (NASDAQ:SNSS)
finance.yahoo.com - February 27 at 9:10 AM
News IconTechnical Trading: Focus on Shares of Sunesis Pharmaceuticals Inc (SNSS) - Davidson Register (NASDAQ:SNSS)
davidsonregister.com - February 25 at 3:27 AM
News IconAre Analysts Optimistic About Where Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) is Heading? - Winfield Review (NASDAQ:SNSS)
winfieldreview.com - February 25 at 3:27 AM
News IconUnusual Volume Spotted in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Stock - Winfield Review (NASDAQ:SNSS)
winfieldreview.com - February 24 at 7:40 AM
News IconMarket Scout: Checking the Levels for Sunesis Pharmaceuticals Inc (SNSS) - Baxter Review (NASDAQ:SNSS)
baxternewsreview.com - February 24 at 7:40 AM
News IconSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Bearish Target At $5 - Stock Observer (NASDAQ:SNSS)
www.thestockobserver.com - February 22 at 8:08 PM
News IconSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Quarterly EPS At $-0.46 - Stock Observer (NASDAQ:SNSS)
www.thestockobserver.com - February 18 at 6:56 PM
seekingalpha.com logoSunesis Pharmaceuticals (SNSS) Presents at 19th Annual BIO CEO & Investor Conference (NASDAQ:SNSS)
seekingalpha.com - February 15 at 6:07 AM
News IconSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Daily Sentiment Score At 0.56 - Stock Observer (NASDAQ:SNSS)
www.thestockobserver.com - February 13 at 12:52 AM
finance.yahoo.com logoSunesis Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference - Yahoo Finance (NASDAQ:SNSS)
finance.yahoo.com - February 6 at 8:19 AM
feeds.benzinga.com logoSunesis Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference (NASDAQ:SNSS)
feeds.benzinga.com - February 6 at 7:42 AM
News IconQuarterly EPS Of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS ... - Stock Observer (NASDAQ:SNSS)
www.thestockobserver.com - January 29 at 9:08 PM
News IconSunesis Pharmaceuticals Inc SNSS Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:SNSS)
www.bioportfolio.com - January 28 at 8:01 PM
News IconEarnings in Full Force, Analysts Take Aim at Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) - Wall Street Beacon (NASDAQ:SNSS)
wsbeacon.com - January 28 at 6:38 AM
News IconWhat are Analysts Expecting for Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Earnings? - Aiken Advocate (NASDAQ:SNSS)
aikenadvocate.com - January 25 at 6:00 AM
nasdaq.com logoSunesis Offers Updates on SNS-062 and Qinprezo Programs ... - Nasdaq (NASDAQ:SNSS)
www.nasdaq.com - January 25 at 6:00 AM
finance.yahoo.com logoSunesis Offers Updates on SNS-062 and Qinprezo Programs (NASDAQ:SNSS)
finance.yahoo.com - January 25 at 6:00 AM
News IconMA Watch on Shares of Sunesis Pharmaceuticals Inc. (SNSS) - Sherwood Daily (NASDAQ:SNSS)
sherwooddaily.com - January 24 at 2:39 AM
streetinsider.com logoSunesis Pharmaceuticals (SNSS) Says SNS-062 IND Application ... - StreetInsider.com (NASDAQ:SNSS)
www.streetinsider.com - January 24 at 2:39 AM
streetinsider.com logoSunesis Pharmaceuticals (SNSS) Says SNS-062 IND Application with FDA is Now Active, Continues Progress with Vosaroxin MAA (NASDAQ:SNSS)
www.streetinsider.com - January 23 at 9:39 PM
seekingalpha.com logoSunesis Pharmaceuticals updates on SNS-062 and Vosaroxin programs (NASDAQ:SNSS)
seekingalpha.com - January 23 at 9:41 AM
finance.yahoo.com logoSunesis Pharmaceuticals Announces Clinical and Regulatory Updates to SNS-062 and Vosaroxin Programs (NASDAQ:SNSS)
finance.yahoo.com - January 23 at 8:33 AM
finance.yahoo.com logo7:01 am Sunesis Pharma announces its IND application with the FDA is now active; recently received the Day 180 List of Outstanding Issues issued by the CHMP as part of the centralized review process (NASDAQ:SNSS)
finance.yahoo.com - January 23 at 8:33 AM
News IconWall Street Holds Inauguration Gains, How Did This Stock Fare: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) - Wall Street Beacon (NASDAQ:SNSS)
wsbeacon.com - January 22 at 5:43 AM
News IconLooking at Moving Averages for Sunesis Pharmaceuticals Inc. (SNSS) - Rives Journal (NASDAQ:SNSS)
rivesjournal.com - January 21 at 1:31 AM
News IconSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Quarterly EPS Set At $-0.46 - Stock Observer (NASDAQ:SNSS)
www.thestockobserver.com - January 21 at 1:31 AM
News IconWhat are the Levels Indicating for This Stock: Sunesis Pharmaceuticals Inc. (SNSS) - Sherwood Daily (NASDAQ:SNSS)
sherwooddaily.com - January 20 at 6:46 AM
News IconSunesis Pharmaceuticals Inc. (NASDAQ:SNSS) Is Attracting Smart Money - Small Cap Exclusive (press release) (NASDAQ:SNSS)
smallcapexclusive.com - January 16 at 6:18 PM
News IconSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Daily Sentiment ... - Stock Observer (NASDAQ:SNSS)
www.thestockobserver.com - January 16 at 1:17 PM
News IconWill The Needle Move For Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:SNSS)
wsbeacon.com - January 14 at 6:19 AM
News IconSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Bearish Target At ... - Stock Observer (NASDAQ:SNSS)
www.thestockobserver.com - January 11 at 4:24 AM
News IconDaily Sentiment Score Of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) At 0.31 - Stock Observer (NASDAQ:SNSS)
www.thestockobserver.com - January 8 at 7:55 PM
investornewswire.com logoSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Strong Buy Recommendations At 2 - Investor Newswire (NASDAQ:SNSS)
www.investornewswire.com - December 29 at 7:51 PM
News IconBearish Target Of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) At $14.997 - Stock Observer (NASDAQ:SNSS)
www.thestockobserver.com - December 29 at 12:47 AM
insidermonkey.com logoIs Sunesis Pharmaceuticals, Inc. (SNSS) A Good Stock To Buy? (NASDAQ:SNSS)
www.insidermonkey.com - December 21 at 12:48 AM
insidermonkey.com logoIs Sunesis Pharmaceuticals, Inc. (SNSS) A Good Stock To Buy? - Insider Monkey (blog) (NASDAQ:SNSS)
www.insidermonkey.com - December 20 at 7:47 PM
News IconSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Quarterly EPS ... - Stock Observer (NASDAQ:SNSS)
www.thestockobserver.com - December 16 at 8:45 PM
News IconCCI Level Check for Sunesis Pharmaceuticals Inc. (SNSS) - Yankee Analysts (NASDAQ:SNSS)
yankeeanalysts.com - December 16 at 3:43 PM
investing.com logoSunesis Pharmaceuticals: Sunesis Shines At ASH (NASDAQ:SNSS)
www.investing.com - December 15 at 5:24 AM
News IconSEC Insider Narrative: Geoffrey Parker, Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)'s insider Invested in 3740 ... - Thorold News (NASDAQ:SNSS)
www.whatsonthorold.com - December 13 at 12:59 AM
News IconSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Quarterly EPS Seen At $-0.46 - Stock Observer (NASDAQ:SNSS)
www.thestockobserver.com - December 10 at 8:07 AM
News IconSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Bearish Target At $14.997 - Stock Observer (NASDAQ:SNSS)
www.thestockobserver.com - December 7 at 8:32 AM
News IconNarrowing in on Trading Indicators for Sunesis Pharmaceuticals Inc. (SNSS) - Yankee Analysts (NASDAQ:SNSS)
yankeeanalysts.com - December 7 at 8:32 AM
directorstalkinterviews.com logoSunesis Pharmaceuticals Announces Presentation of Updated Results from the VALOR Trial Examining Overall ... - DirectorsTalk Interviews (NASDAQ:SNSS)
www.directorstalkinterviews.com - December 6 at 8:31 AM
News IconStock News Sentiment Of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) In Focus - Stock Observer (NASDAQ:SNSS)
www.thestockobserver.com - December 5 at 7:43 PM
News IconSunesis Pharmaceuticals Announces Presentation of Updated Results from the VALOR Trial Examining Overall ... - EconoTimes (NASDAQ:SNSS)
www.econotimes.com - December 5 at 7:43 PM
smarteranalyst.com logoStock Update (NASDAQ:SNSS): Sunesis Pharmaceuticals, Inc. Announces Presentation of Results from Completed ... - Smarter Analyst (NASDAQ:SNSS)
www.smarteranalyst.com - December 5 at 7:43 PM
finance.yahoo.com logoSunesis Pharmaceuticals Announces Presentation of Updated Results from the VALOR Trial Examining Overall Survival in Patients Age 60 Years and Older with Relapsed/Refractory AML at the ASH Annual Meeting (NASDAQ:SNSS)
finance.yahoo.com - December 5 at 7:43 PM
us.rd.yahoo.com logoSunesis Pharmaceuticals Announces Presentation of Results from Completed Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK inhibitor SNS-062 at ASH Annual Meeting (NASDAQ:SNSS)
us.rd.yahoo.com - December 5 at 9:02 AM
us.rd.yahoo.com logo7:08 am Sunesis Pharma presents results from its Phase 1A study in healthy volunteers evaluating oral non-covalent reversible BTK inhibitor SNS-062 at ASH 2016 (NASDAQ:SNSS)
us.rd.yahoo.com - December 5 at 9:02 AM

Social

What is Sunesis Pharmaceuticals' stock symbol?

Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."

When will Sunesis Pharmaceuticals announce their earnings?

Sunesis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

What are analysts saying about Sunesis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock:

  • According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (1/19/2017)

  • Cowen and Company analysts commented, "Sunesis intends to respond to the EMA’s Day 120 questions on vosaroxin for r/r AML." (7/29/2016)

Who owns Sunesis Pharmaceuticals stock?

Sunesis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Aisling Capital IV, LP (6.20%), Patrick Lee, MD (5.57%), Palo Alto Investors LLC (5.57%), Boxer Capital LLC (2.51%), Vivo Capital LLC (2.39%) and Renaissance Technologies LLC (0.53%). Company insiders that own Sunesis Pharmaceuticals stock include Daniel N Swisher Jr, Dayton Misfeldt and Geoffrey M Parker.

Who bought Sunesis Pharmaceuticals stock? Who is buying Sunesis Pharmaceuticals stock?

Sunesis Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Vivo Capital LLC and Renaissance Technologies LLC. Company insiders that have bought Sunesis Pharmaceuticals stock in the last two years include Daniel N Swisher Jr, Dayton Misfeldt and Geoffrey M Parker.

How do I buy Sunesis Pharmaceuticals stock?

Shares of Sunesis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Sunesis Pharmaceuticals stock cost?

One share of Sunesis Pharmaceuticals stock can currently be purchased for approximately $4.30.

Sunesis Pharmaceuticals (NASDAQ:SNSS) Chart for Tuesday, February, 28, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Earnings History Chart

Earnings by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Dividend History Chart

Dividend Payments by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Last Updated on 2/28/2017 by MarketBeat.com Staff